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INTRODUCTION
From all dimensions and symptoms that
makes difficult to live with cancer, Pain is
probably the most unpleasant and detri-
mental symptom for the quality of life.
Whether it is in the active or palliative treat-
ment phase, or if the patient is a Cancer sur-
vivor, no single achievement in the re-struc-
tured life of these patients after their diag-
nosis is made can be enjoyable if uncon-
trolled Pain is present. 
The pourpose of this paper is to present a
wide scope of our current view of the general
context, ethiology, mechanisms, and the treat-
ment approaches from the basis to the most
refined and updated interventions in order to
control cancer pain. Its relation to decision-
making in palliative care is remarked when
feasible, and the final target is to serve as a ref-
erence paper for the non-pain specialist in a
daily multidimensional practice towards qual-
ity of life improvement in patients remarkably
associated with severe pain.
Cancer pain is defined as pain that is attrib-
utable to cancer or its therapies(1). The more
general and accepted definition of pain as “an
unpleasant sensory and emotional experience
associated with actual or potential tissue dam-
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age, or described in terms of such damage”(2)
relates better to Palliative Care, on which dai-
ly practice every symptom is deeply influenced
by the context, the expectations and all type of
emotional experiences of the cancer patient.
Cancer pain is a problem that has attained a
rising level of recognition among the health
care community. Optimal management
involves careful assessment, optimal analge-
sia, intensive follow-up and a proactive
approach to treatment. Adequate control of
pain can be achieved in the majority of patients
with a rigorous and aggressive application of a
treatment algorithm that is ultimately quite
straightforward(3, 4). Control of pain and related
symptoms promotes an enhanced quality of
life, improved functioning, better compliance
and a means for patients to focus on those
things that give meaning to life(5). In addition to
their salutary effects on quality of life, mount-
ing evidence suggests that good pain control
influences survival(6,7).
Approximately 6.35 million new cases of
cancer are diagnosed worldwide annually,
half of which originate in developing
nations(8). The WHO estimates that by the
year 2021, there will be 15 million new ca-
ses of cancer worldwide annually. This will
lead to cancer patients living longer with
pain due to cancer disease itself and with
therapy, which brings the need for a better
symptom control in extreme situations both
for pain and for other symptoms in Palliative
Care. Approximately 1.04 million new diag-
nosis of cancer are made annually in the
United State alone(9). One of every five death
in the United States is a result of cancer,
which is approximately 1400 cancer related
death daily(10). The incidence of cancer
increases with age and is particularly prob-
lematic given our rapidly aging population.
It is estimated that up to 50% of patients
undergoing treatment for cancer and up to
90% of patients with advanced cancer have
pain(11). Most (70%) cancer pain is due to
tumor involvement of organic structures,
notably bone, neural tissue, viscera, or oth-
ers. Up to 25% of cancer pain is due to ther-
apy, including chemotherapy, radiotherapy,
or surgery. Up to 10% of “cancer pain” is
accounted for by common chronic pain syn-
dromes, including back pain and headaches,
which might have been exacerbated by the
ongoing growth or treatment of cancer(12).
Overall, cancer cure rates have not
changed markedly over the past 4 decades:
the overall 5-year survival rate for patients
diagnosed with cancer in United States is still
only about 40 to 50 %(13) and as a result of
inadequate early detection, is less than one
third worldwide(8). The annual mortality rate
is about 4.3 million worldwide and about
510,000 in the United States(9). Palliative
treatment, which may extend survival, is often
more successful than therapies with curative
intent, and as a result, there is an increasing
number of patients to bearing advanced dis-
ease with associated chronic pain. Further-
more, the last decades advances in cancer
treatment has increased not only the life
expectancy but the number of survivors of a
once fully mortal disease, increasing also the
number of patients residual pain from cancer
treatment that needs palliative treatment. 
CANCER PAIN STATISTICS 
Together with anorexia and fatigue, pain
is among the most common symptom associ-
ated with cancer(14,15). Significant pain is pres-
ent in up to 25% of patients in active treat-
ment and in up to 90% of patients with
advanced cancer(11, 16 -20). According to sever-
al studies including a survey of oncologists in
the Eastern Cooperative Oncology Group
(ECOG) and a survey of 1103 consecutive
admission to a U.S tertiary care cancer hospi-
tal, 73% of patients in active treatment admi-
tted to pain with 38 % reporting severe
pain(21). Despite the availability of simple,
cost-effective treatment(22), inadequately con-
trolled pain remains a significant problem.
Studies following the WHO cancer pain
ladder (e.g. oral analgesics and careful fol-
low-up) have achieved favorable outcomes
in the 70 to 90 % range(23) suggesting that the
key to achieving more effective global can-
cer pain relief involves applying known tech-
nology more effectively rather than develop-
ment of new medical technologies or drugs. 
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While a variety of such factors have been
identified, authorities agree that so-called
“opiophobia”, a reluctance to use opioids,
largely because of exaggerated concerns of
addiction and regulatory reprisal, exerts a
potent influence at all levels and probably is
the single most important impediment to bet-
ter symptom control globally. In general, in
Western developed sectors, barriers are
largely educational and attitudinal in nature,
while in developed nations a multitude of
resource and access problems are operant.
As an example, negative indirect effects on
survival may stem from the negative influ-
ence of pain on performance status. When
performance status is low, as is often the case
when pain is severe, patients may find it dif-
ficult to tolerate recommended chemothera-
py, indeed they may not be considered can-
didates for chemotherapy. Further benefits of
good pain management often include
improvements in nutrition, rest and mood, all
of which contribute to quality of life and have
the potential to influence the outcome of
antineoplastic therapy.
EVALUATION AND ASSESSMENT
Pain is always subjective and is experi-
enced only by the patient. Over the past 20
years, the assessment of pain has been the
subject of much research and refinement of
techniques and instruments, from which the
most relevant are described below:
Many pain clinics utilize a question-
naire to aid in and standardize assessment.
The Wisconsin Brief Pain Inventory
(BPI)(24,25) and Memorial pain assessment
card(26) are well accepted and standard tools
for assessing cancer pain. At The Universi-
ty of Texas MD Anderson Cancer Center, an
institutionally approved MD Anderson
questionnaire (modified BPI) is used for ini-
tial and follow-up assessment of patients. 
Numerous tools are available for assess-
ing cancer related pain including:
1. Wisconsin Brief Pain Inventory: 
a. 15-minute questionnaire, which can
be self-administered.
b. Includes several questions about the
characteristics of pain, including its ori-
gin and their effects of prior treatments.
c. It incorporates two valuable features
of the McGill Pain Questionnaire, a
graphic representation of the loca-
tion of pain and groups of qualitative
descriptors. Severity of pain is
assessed by a series of VAS that score
pain at its best, worst and on aver-
age. The perceived level of interfer-
ence with normal function is quanti-
fied with VAS also.
Preliminary evidence suggests that
the BPI is cross-culturally valid(24,25)
and is useful, particularly when
patients are not fit to complete a
more through or comprehensive
questionnaire. 
2. Memorial Pain Assessment Card:
a. It is a simple efficient, and valid
instrument that provides rapid clini-
cal evaluation of the major aspects
of pain experienced by cancer
patients(26).
b. It is easy to understand and use and
can be completed by experience
patients in 20 seconds.
c. It consists of two-sided 8.5x11 inch
card that is folded so that four sepa-
rate measures are created.
d. It features scales, intended for the
measurements of pain intensity, pain
relief, mood and a set of descriptive
adjectives.
3. Edmonton Staging System:
a. It is performed by health care
providers
b. It was developed to predict the like-
lihood of achieving effective relief of
pain in cancer patients(27,28).
c. The system’s originators have provid-
ed validation that treatment outcome
can be accurately predicted accord-
ing to five clinical features (Neuro-
pathic pain, movement-related pain,
recent history of tolerance to opioids,
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psychological distress, and a history
of alcoholism or drug abuse).
d. Staging requires only 5-10 minutes
and requires no special skills.
e. Its value lies in prospective identifica-
tion of potentially problematic patients,
further legitimizing clinical research on
symptom control by introducing better
standardization and improving our
ability to assess critically the results of
various therapeutic interventions in
large population of patients. 
4. Pediatric Cancer Pain Assessment:
This includes Beyer’s The Oucher, Eland’s
color scale-body outline, Hester’s poker chip
tool, McGrath’s faces scale, and others(29-32).
5. Numerical Pain Rating Scale (NRS) or
Visual Analog Scale (VAS):
Pain is assessed on an 11 point numeri-
cal rating scale from 0 (no pain) to 10 (worst
pain imaginable). The VAS is a 10 cm line
without markings from no pain to worst pain;
the patient marks their pain score and a meas-
urement in cm defines their level of pain.
Objective observations of grimacing,
limping, and vital signs (tachycardia) may be
useful in assessing the patient, but these signs
are often absent in patients with chronic can-
cer pain. Pain evaluation should be integra-
ted with a detailed oncological, medical, and
psychological assessment. The initial evalua-
tion should include evaluation of person, his
or her feelings and attitudes about the pain
and disease, family concerns and the patient’s
pre-morbid psychological history. A compre-
hensive but objective approach to assessment
generates confidence in the patients and fami-
ly that will be valuable throughout treatment.
A comprehensive evaluation of the
patients with cancer pain includes the fol-
lowing:
1. The chief complaint is obtained to
ensure appropriate categorization or triage
(e.g. severe pain with a bowel obstruction
may need to be sent to the emergency cen-
ter for urgent treatment). 
2. Next, the oncologic history is
obtained to gain the context of the pain
problem. The oncologic history includes:
diagnosis and stage of disease, therapy and
outcome-including side effects, and the
patient’s understanding of the disease
process and prognosis.
3. The pain history should include any
premorbid chronic pain and for each new
pain site must include: Onset and evolution,
site and radiation, pattern (constant, inter-
mittent, or unpredictable), intensity (best,
worst, average, current) 0-10 scales, quali-
ty, exacerbating and relieving factors, pain
interference with usual activities, neurolo-
gical and motor abnormalities (including
bowel and bladder continence), vasomotor
changes, current and past analgesics (use,
efficacy, side effects). Prior analgesic use,
efficacy, and side effects should be cata-
loged. Prior treatments for pain should be
noted (radiotherapy, nerve blocks, physio-
therapy, etc.) 
4. Review of medical record and radi-
ological studies: Many of the treatments for
cancer can cause pain themselves
(chemotherapy, and radiotherapy induced
neuropathies or postoperative pain syn-
dromes; post-thoracotomy pain syndromes
and post-mastectomy pain syndrome), and
many specific cancers can cause well esta-
blished pain patterns due to known likely
sites of methastasis as: a) Breast to long
bones, spine, chest wall, brachial plexus,
and spinal cord, b) Colon to pelvis, hips,
lumbar plexus, sacral plexus and spinal
cord, c) Prostate to long bones, pelvis, hips,
lung and spinal cord.
5. Psychological History: This should
include marital and residential status,
employment history and status, educatio-
nal background, functional status, activities
of daily living, recreational activities, su-
pport systems, health and capabilities of
spouse or significant other, past history of
(or current) drug or alcohol abuse.
6. Medical History (independent of
oncological history) including coexisting
systemic disease, exercise intolerance,
allergies to medications and medication
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use, prior illness and surgery, and a tho-
rough review of systems Including the fol-
lowing systems:
a. General (including anorexia, weight
loss, cachexia, fatigue, weakness,
insomnia)
b. Neurologic (including sedation,
confusion, hallucination, heada-
che, motor weakness, altered sensa-
tion, incontinence)
c. Respiratory (including dyspnea,
cough, pneumonia)
d. Gastrointestinal (including dyspha-
gia, nausea, vomiting, constipation,
diarrhea)
e. Psychological (Including irritability,
anxiety, depression, dementia)
f. Genitourinary (including urgency,
hesitancy, or hematuria)
7. Physical Examination : The physical
examination must be thorough although at
times it is appropriate to perform a focused
examination. In patients with spinal pain,
and known or suspected metastatic disease a
complete neurologic exam is mandatory. A
detailed physical examination can find new
evidence of metastatic disease in nearly 64%
of patients referred to a Pain Service, resul-
ting in anti-tumor therapy for 18% of patients.
8. Determination of need for further
studies.
9. Formulate clinical impression (diag-
nosis by symptom, ethiology,and mecha-
nism ). Multiple diagnosis usually apply and
it is optimal to use the most specific known
diagnosis. For example: 1) T-11 compres-
sion fracture (pathologic versus osteoporot-
ic) with severe pain, 2) Metastatic breast
carcinoma (with known bony metastasis), 3)
Nausea with inanition, 4) Constipation. 
10. Formulate recommendations (Plan)
and alternatives for each problem. For exam-
ple (related to the above problem list): 1) MRI
of the T-Spine with consideration of vertebro-
plasty if appropriate. 2) Oxycodone-slow
release 10 mg twice daily, with oral transmu-
cosal fentanyl citrate for breakthrough pain.
3) Management including further chemother-
apy, radiotherapy, or bisphosphonates in
coordination with the patient’s oncologist. 4)
Metoclopramide 10 mg po 30 min prior to
meals and as needed for nausea. 5) Addition
of senekot-S twice daily for constipation.
11. Call oncologist and/or primary care
provider if applicable
12. Exit interview
– Explain the probable cause of symptoms
in terms the patient can understand.
– Discuss prognosis for symptom relief,
management options and specific re-
commendations. In addition to writing
prescriptions, oral and written instruc-
tions must be provided. Educational
material regarding medications, pain
management strategies, procedures,
or others should be provided. Poten-
tial side effects should be discussed.
– Arrange for follow-up with clinic
contact information.
– A dictated summary should be sent to
referring and consulting physicians to
keep them appraised of the patient’s




1. Acute Pain: It is frequently associa-
ted with sympathetic hyperactivity and
heightened distress(33). It is often temporally
associated with the onset or recrudescence
of primary or metastatic disease, and its
presence should motivate the clinician to
seek its cause aggressively and need for
more potent analgesics.
2. Subacute Pain: The pain that some
patients experience for 4-6 weeks after a
major surgical procedure. This type of pain
is largely under-treated and deserves special
attention as it may affect patient’s ability to
perform activities of daily living after dis-
charged from the hospital.
3. Chronic Pain: Treating pain of a
chronic nature mandates a combination of
palliation, adjustment and acceptance.
With time, a biological and behavioral
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adjustment to symptoms occurs, and hope-
fully associated symptoms are blunted.
Chronic pain with superimposed episodes
of acute pain (breakthrough pain) is proba-
bly the most common pattern observed in
patients with ongoing cancer pain.
Intensity
The consistent use of measurements of
pain intensity aids in following a patient’s
progress and may serve as a basis for inter-
patient comparisons. High pain scores may
alert the clinician to the need for more
aggressive treatment (see figure 1. MDACC
treatment algorithm)
Pathophysiology
This approach is useful when formulat-
ing the initial approach to treatment.
1. Somatic nociceptive pain is described
as a constant, well-localized pain often cha-
racterized as aching, throbbing, sharp or gnaw-
ing. It tends to be opioid responsive and
amenable to relief by interruption of proximal
pathways by neural blockade when indicated.
2. Visceral nociceptive pain originates
from injury to organs. This pain is transmit-
ted via fibers in the sympathetic nervous sys-
tem(34). Visceral pain is characteristically
vague in distribution and quality and is often
described as deep, dull, aching, dragging,
squeezing or pressure like sensation. When
acute, it may be paroxysmal and colicky and
can be associated with nausea, vomiting,
diaphoresis, and alterations in blood pres-
sure and heart rate. Mechanisms of visceral
pain include abnormal distension or con-
traction of the smooth muscle walls (hollow
viscera), rapid capsular stretch (solid vis-
cera), ischemia of visceral muscle, serosal or
mucosal irritation by algesic substances and
other chemical stimuli, distension and trac-
tion or torsion on mesenteric attachments
and vasculature, and necrosis(35) . The vis-
cera are, however, insensitive to simple
manipulation, cutting and burning(34). Vis-
ceral involvement often produces referred
pain(36, 37) (e.g. phrenic nerve-mediated
shoulder pain of hepatic origin).
3. Neuropathic pain is defined as pain
emanating from the nervous system due to
injury or irritation to some element of the
nervous system. Examples of neuropathic
pain syndromes associated with cancer are
depicted in Table 1.
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Table 1. Examples of Neuropathic Pain Syndromes
Example of Neuropathic Cancer Pain Syndromes
Due to Tumor Growth or
Humoral Activity
Due to Surgical Nerve Trauma
Due to Medical Treatment
• Paraneoplastic Polineuropathies
• Brachial Plexus Plexopathy
• Lumbar Plexus Plexopathy
• Skull Base Syndromes
• Spinal Cord Compresion
• Post Thoracotomy Pain
• Post Mastectomy Pain
• Post Amputation /Phantom Pain
• Post Chemotherapy Neuropathies
• Post Irradiation Brachial Plexopathy
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Figure 1. MDACC treatment algorithm
Neuropathic pain is often resistant to
standard analgesic therapies and often
requires an approach utilizing opioids, anti-
convulsants, oral or topical local anesthetics,
corticosteroids, NMDA blockers and others. 
Temporal aspects of Pain:
1. Constant Pain: This pain is most
amenable to drug therapy administered
around the clock, contingent on time rather
then symptoms. It is best managed by long-
acting analgesics or in selected cases, infu-
sion of analgesics.
2. Breakthrough Pain and Incident Pain:
Breakthrough pain that is related to a specif-
ic activity, such as eating, defecation, socia-
lizing or walking is referred to as incident
pain. Breakthrough pain is best managed by
supplementing the preventative around-the-
clock regimen with analgesics with a rapid
onset of action and a short duration. Once a
pattern of incident pain is established, escape
or rescue, doses of analgesics can be admi-
nistered in anticipation of the pain provoking
activity. Breakthrough pain that occurs con-
sistently prior to the next scheduled dose of
around-the clock opioids is called “end of
dose failure” and is related to the decrease in
plasma concentrations of the analgesics
below minimum effective analgesic concen-
trations (MEAC). “End of dose failure” is ide-
ally managed by increasing the dose of the
basal analgesic or reducing the intervals
between doses. Refractory incident pain
often is responsive to stabilization, such as
fixation of a pathologic fracture or vertebro-
plasty for a vertebral compression fracture.
3. Intermittent Pain: This is very unpre-
dictable and can be best managed by
administration of immediate release potent
analgesics of rapid onset and short duration.
Specific Cancer Pain Syndromes
1. Osseous invasion or tumor infiltra-
tion of the bone is cited as the most com-
mon cause of cancer pain and is most often
seen in metastatic carcinoma of the
prostate, breast, thyroid, lung, or kidney(39-
41). The presentation of bone metastatic pain
is variable; usually a constant deep dull
ache, often greatest at night and with move-
ment or weight bearing, complicated by
paroxysms of stabbing pain. Approximately
25% of patients with bone metastasis expe-
rience severe pain. Somatic and sympathet-
ic fibers carry pain(42,43). A bone scan (Iso-
tope Scanning, Scintigraphy) is preferred for
detecting most bone metastasis(39).
Prostaglandin E2 (PGE2) and other
cytokines are elaborated by osseous metas-
tasis. These cytokines are felt to contribute
to pain by sensitization of peripheral
periosteal nociceptors in addition to caus-
ing central sensitization. NSAIDs and
steroids are postulated to reduce pain from
bony metastasis via inhibition of the cyclo-
oxygenase pathway of arachidonic acid
breakdown, thus decreasing the formation
of PGE2. The cox-2 selective anti inflamma-
tories have been shown in a murine sarco-
ma bone metastasis model to effectively
inhibit spontaneous and movement related
bone pain, reduce biochemical markers of
peripheral and central sensitization, reduce
tumor induced osteoclastic proliferation,
and finally to reduce overall tumor bur-
den(42-44). As deposits enlarge, stretching of
the periosteum, pathological fracture and
perineural invasion contribute to pain and
requirements for analgesics increase. Pallia-
tive radiation is commonly successfully
employed to relieve pain emanating from
bony metastasis. Hormonal therapy
(chemotherapy such as tamoxifen or
leuprolide, orchiectomy, or rarely hypophy-
sectomy) often reduces bony pain in
patients with hormonal dependant disease
(Breast, Prostate). In general, the hormone
refractory breast and prostatic carcinomas
are less responsive to treatment 45,46). 
2. Vertebral body metastasis is most
commonly associated with metastatic carci-
noma of the lung, breast and prostate. Local-
ized paraspinal, radicular or referred pain is
usually the first sign of metastasis to the bony
vertebral column. The pain is often described
as severe local, dull, steady, aching, often
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exacerbated by recumbence, sitting, move-
ment and local pressure; may be relieved by
standing; local midline tenderness may be
present; associated nerve compression may
produce radiating dermatomal pain and cor-
responding neurological changes. A special
warning must be made here to avoid the most
undesirable complication of vertebral body
metastasis, that can be avoided in most cas-
es simply by suspiction and a routinely per-
formed neurological examination: an epidur-
al-spinal cord compression(47).
3. Base of skull metastasis: Usually
present with headache and a spectrum of
neurological findings, especially involving
cranial nerves. Symptomatic metastasis to
the skull is usually - but not always- a late
finding(48). Plain X-ray, Scintigraphy, and CT
scan are helpful for diagnosis of bony dis-
ease, while MRI and lumbar puncture are
useful to evaluate the soft tissue and to detect
leptomeningeal disease, respectively(49). 
4. Visceral pain is usually seen in gas-
trointestinal malignancies due to direct
tumor and invasion of visceral structures.
This pain is transmitted via fibers in the sym-
pathetic nervous system(34). Visceral pain is
characteristically vague in distribution and
quality and is often described as deep, dull,
aching, dragging, squeezing or pressure like
sensation. When acute, it may be paroxys-
mal and colicky and can be associated with
nausea, vomiting, diaphoresis, and alter-
ations in blood pressure and heart rate.
Mechanisms of visceral pain include abnor-
mal distension or contraction of the smooth
muscle walls (hollow viscera), rapid capsu-
lar stretch (solid viscera), ischemia of viscer-
al muscle, serosal or mucosal irritation by
algesic substances and other chemical stim-
uli, distension and traction or torsion on
mesenteric attachments and vasculature,
and necrosis(34,35). Visceral involvement
often produces referred pain(36,37) (e.g.
phrenic nerve-mediated shoulder pain of
hepatic origin). The classic cancer visceral
pain syndrome is pancreatic cancer related
pain. This pain is described as relentless,
mid-epigastric aching, which radiates
through to the mid-back, often relieved by
the fetal position and worsened by recum-
bence. These visceral pains can be extraor-
dinarily helped with sympathetic visceral
neurolytic blockade(50,51).
5. Musculo-skeletal pain is probably
under diagnosed in cancer patients. Undere-
cognition is probably due in part to the inabil-
ity of standard radiographic technique to do-
cument muscle injury, as well as the varied,
sometimes vague, and usually non-neurolog-
ical constellation of characteristic symptoms.
6. Nerve invasion: Typically constant,
burning dysesthetic pain, often with an
intermittent lancinating, electrical compo-
nent; may be associated with neurologic
deficit or diffuse hyperesthesia or hypesthe-
sia and localized parasthesia; muscle weak-
ness and atrophy may be present in mixed
or motor nerve syndromes(52-55).
7. Leptomeningeal metastasis, menin-
geal carcinomatosis: Most common with
primary malignancies of breast and lung;
lymphoma and leukemia; it is secondary to
diffuse infiltration of meninges; About 40%
of patients have headache or back pain, pre-
sumably due to traction on the pain-sensi-
tive meninges, cranial, and spinal nerves
and/or raised intracranial pressure(56,57).
Headache is most common presenting
complaint; characteristically unrelenting;
may be associated with nausea, vomiting,
nuchial rigidity and mental status
changes(57); associated neurological abnor-
malities may include seizures, cranial nerve
deficits, papilledema, hemiparesis, ataxia
and cauda syndrome; diagnosis confirmed
with lumbar puncture and CSF analysis,
which revealed the presence of malignant
cells, and may also be remarkable for an
increased opening pressure, raised protein,
and decreased glucose(58). CT or MRI are
also recommended and may reveal plaque-
like tumor. The natural history of patients
with leptomeningeal metastasis is gradual
decline and death over 4-6 weeks, although
survival is often extended to 6 months or
more when treatment with radiation thera-
py and/or intrathecal chemotherapy is insti-
tuted(59). Steroids may be useful in the man-
agement of headache(49).
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8. Spinal cord compression is usually
heralded by pain in the presence of neuro-
logical changes. An urgent radiological
work-up in mandatory in the face of neuro-
logical deficits, particularly motor weak-
ness, band-like encircling pain or inconti-
nence. Prompt treatment in form of radio-
therapy or spinal stabilization may limit
neurologic morbidity(47) . 
9. Plexopathies are syndromes of tumor
invasion into the nerve plexus in the upper
of lower extremity. Cervical plexopathy is
most commonly caused by local invasion of
head and neck cancers or from enlarged
lymph nodes. Symptoms are primarily senso-
ry in the distribution of plexus, experiencing
as aching pre-auricular, post-auricular, or
neck pain. Brachial plexopathy is most com-
monly due to upper lobe lung cancer (called
the Pancoast syndrome or superior sulcus
syndrome), breast cancer or lymphoma; pain
is an early symptom, usually preceding neu-
rological findings by up to 9 month(52,53), . The
lower cord of the plexus (C8-T1) is affected
most frequently, and pain is usually diffuse
aching in shoulder girdle, radiating down
arm, often to the elbow and medial (ulnar)
aspect of the hand(54,55). When the upper
trunk is involved (C5-6), pain is usually in the
shoulder girdle and upper arm, radiating to
the thumb and index finger. Horner’s syn-
drome, dysesthesias, progressive atrophy,
and neurological impairment (weakness and
numbness) may occur. In some situations the
clinical presentation may be difficult to dif-
ferentiate from radiation fibrosis, which cha-
racteristically is less severe, less often associ-
ated with motor changes, tends to involve the
upper trunks, and may be associated with
lymphedema(52,60) without a Horner’s sign.
Brachial plexus invasion may be associated
with contiguous spread to the epidural
space(60-62). Lumbo-sacral plexopathy may be
due to local soft tissue invasion or compres-
sion occur most commonly with tumors of
the rectum, cervix, breast, sarcoma, and lym-
phoma; pain is usually the presenting symp-
tom in 70% of patients(63); The pain is usual-
ly described as aching or pressure-like and
only rarely dysesthetic. Depending on the
level involved, pain is referred to the low
back, abdomen, buttock, or lower extremi-
ty(63, 64). Reflex asymmetry and mild sensory
and motor changes when present, were rel-
atively early findings, whereas impotence
and incontinence are relatively rare. This
syndrome must be differentiated from spinal
cord invasion or cauda equina syndrome in
which urgent diagnosis and treatment is
mandatory.
10. Chemotherapy Related 
a. Oral mucositis usually occurs in 1-2
weeks of the initiation of chemother-
apy. This condition is most common
with the use of methotrexate, dox-
orubicin, daunorubicin, bleomycin,
etoposide, 5-fluorouricil, and dacti-
nomycin(65) . Mucositis is often most
severe when chemotherapy is com-
bined with radiation treatments to
the head and neck region.
b. Painful polyneuropathy occurs most
commonly with vincristine (motor and
sensory involvement), vinblastine, tax-
ol taxotere, the platinum derivative
(predominantly sensory involvement),
and navelbine(66); Symptoms com-
monly include burning, dysesthetic
pain in the hands and feet.
11. Post-surgical chronic pain syndromes
are most common after mastectomy, thora-
cotomy, radical neck dissection, nephrecto-
my and amputation(67). The clinical charac-
teristics usually include aching, shooting, or
tingling pain in distribution of peripheral
nerves (e.g. intercostals-brachial, inter-
costals, cervical plexus) with or without skin
hypersensitivity. In one of the study(68), the
incidence of post-mastectomy pain was
higher after conservative surgery than modi-
fied radical mastectomy (33% versus 17%).
In this same study 25 % of patients experi-
enced post-operative phantom breast pain.
The exact incidence of post-surgical pain
syndromes is unclear, but appears to be in the
25-50% range by some estimates(67).
12. Headache is present in 60% of
patients with a primary or metastatic brain
tumor, half of who classified as their primary
complaint(69). It is typically steady, deep, dull,
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and aching with moderate intensity and that is
rarely rhythmic or throbbing. It is usually inter-
mittent and may be worse in the morning and
with coughing-straining. Symptoms often
improve with radiation therapy, non steroidal
anti-inflammatories, or corticosteroids(70-72).
13. Cervicofacial pain syndromes are
most common in patients with head and
neck cancers. The head and neck are rich-
ly innervated by contributions from cranial
nerves V, VII, IX, X and upper cervical
nerves, so pain varies in character. When
cranial nerves are involved, symptoms re-
present those of trigeminal, glossopharyn-
geal, and/or intermittent neuralgia, with
sudden, severe lancinating pain radiating to
the face, throat or ear respectively. 
14. Radiation therapy may be associated
with both acute and chronic pain syndromes.
Acutely, mucositis, cutaneous burns, may be
seen. Chronically, post radiation syndromes
include osteoradionecrosis, myelopathy,
plexopathy, soft-tissue fibrosis, and the emer-
gence of new secondary neurogenic tumors. 
TREATMENT
The goal of treatment of cancer pain is
to relieve pain by modifying its source,
interrupting its transmission, or modulating
its influence at brain or spinal cord sites.
This can be achieved with various means
and combination of following available
modalities (see table 2).
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(A) Antineoplastic Treatment:








V. Oral local anesthetics
VI. Amphetamine
VII. Corticosteroid
VIII. N-Methyl-D-Aspartate (NMDA) Antagonists 
IX. Alpha-2 Adrenergic antagonists
X. Others
(C) Interventional Pain Management
1. Continuous subcutaneous infusion of opioids (CSCI)
2. Continuous intravenous infusion of opioids (CII)
3. Neuraxial analgesia – epidural or intrathecal indusions
4. Neural Blockade Techniques
- Local anesthetic nerve block
- Neurolytic nerve block
5. Vertebrosplastia
6. Neuromodulation
(D) Behavioral pain management
(F) Home-based and hospice care
Table 2. Treatment modalities available for Cancer Pain patients
Antineoplastic Treatment
The most effective form of treatment of
any cancer related pain is treatment of the
cancer itself, which in the majority of cases
will reduce or eliminate the pain. Once
diagnosed, the pathological process
responsible for pain can often be altered
with surgical extirpation, external beam
radiation therapy (targeted fractioned or sin-
gle-dosed therapy, hemi body or total body
irradiation)(73,74), radionuclides (e.g. Stron-
tium-89, Samarium) intrarterial chemother-
apy(75), hormonal treatment(76) and even
whole-body hyperthermia(77). The majority
of patients require some form of primary
analgesic therapy even when pursuing anti-
tumor therapy.
Pharmacological Management
The control of pain involves three basic
principles: modifying the source of the pain,
altering the central perception of pain, and
blocking the transmission of the pain to the
central nervous system. In addition, any
new pain in a patient with cancer is
assumed disease progression or recurrence
until proven otherwise.
Oral analgesics are the mainstay of ther-
apy for patients with cancer pain. An esti-
mated 70-90% of patients can be rendered
relatively free of pain when straightforward
guidelines-based participles applied in a
thorough, careful manner (1,3,4,78). 
The World Health Organization (WHO)
has developed a three-step ladder approach
to cancer pain management that relies
exclusively on the administration of oral
agents and that is usually effective(19,78). Care
must be taken when use of this ladder, as the
evidence was not very strong at the time of
publication(79), and its use should always be
regarded as the pharmachological systemic
approach, usually a part of a more compre-
hensive pain control strategy . When this
conservative therapies produce inadequate
results, escalating doses or alternative ther-
apy should be sought in the shortest possi-
ble time. The role of more invasive forms of
analgesia, ranging from parenteral anal-
gesics to neural blockade or neuraxial anal-
gesia, should be considered judiciously
thenafter, but never delayed if the cause of
pain is locally restricted(50).
Before initiation of therapy, assessment
of problems and setting realistic goals that
are acceptable to the patient should be
established along with a treatment plan and
contingencies. 
The non-invasive route should be main-
tained as long as possible for reasons that
include simplicity, maintenance of inde-
pendence and mobility, convenience, and
cost. Treatment should be directed towards
relief of pain and suffering, which includes
consideration of all aspects of function (e.g.
disturbance of sleep, appetite, mood, activ-
ity, posture, and sexuality), and attention
should be paid not only to physical but also
to emotional, psychological, and spiritual
aspects of suffering. 
The University of Texas MD Anderson
cancer Center published a modified and
condensed version of the National Cancer
Centers Network (NCCN) guidelines, the
general strategy is of stronger opioids and
adjuvants use with more frequent reassess-
ment for higher pain levels. Some basic
principles to manage large population of
patients are described here as pearls for can-
cer pain therapeutics. 
1. Nonsteroidal anti-inflammatory
drugs (NSAID’s)
NSAID’s are most effective for pain of
inflammatory (eg. bone metastasis) origin
by virtue of interference with prostaglandin
(PG) Synthesis(80). Consider the regular
(around-the-clock) administration of an
NSAID as the sole treatment for mild pain
or in combination with opioid analgesic for
moderate or severe pain(1). Potential for ben-
efit should be balanced against potential for
toxicity (which includes upper GI irritation,
renal insufficiency, platelet dysfunction and
masking of fever), which is pertinent in the
context of recent antitumor therapy and
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advanced age(80). Consider avoiding
NSAID’s all together or instituting prophy-
laxis (e.g. Misoprostol, and proton pump
inhibitors as Omeprazol ) in patients predis-
posed to gastropathy.
The nonacetylated salicylate (sodium
salicylate, choline magnesium trisalicylate)
are associated with a favorable toxicity pro-
file, since they fail to interfere with platelet
aggregation, are rarely associated with GI
bleeding, and are well tolerated by asthmat-
ic patients(81,82). A parenteral formulation of
ketorolac is equianalgesic to low doses of
morphine in some settings but is associated
with the same range of side effects as oral
NSAID’s(83).
NSAID’s are associated with s ceiling
effects, above which dose escalations pro-
duce toxicity but no greater analgesia. How-
ever, the ceiling dose for a given drug differs
from patient to patient, allowing some poten-
tial for dose titration. When efficacy is poor,
the clinician may consider rotating to ano-
ther NSAID, usually from a different bio-
chemical class because it is clear that for a
given patient, clinical response differs among
various agents (inter-individual variability),
and there is evidence that various classes of
NSAID’s may exert their anti-PG effects on
different subtypes of cyclo-oxygenases
(COX-1, COX-2)(84), being COX2 the enzyme
primarily responsible for peripheral induc-
tion of inflammatory sensitization . and par-
tially devoided of the adverse COX1 effects
on gastric mucosa, there may be a better safe-
ty profile of the newer COX-2 inhibitors in
cancer patients versus the traditional
NSAIDs, which are non-specific inhibitors of
COX-1 and COX-2., with potential advan-
tage in some type of cancers to reeduce
tumor burden, but clearly not producing bet-
ter analgesia than non selective NSAIDs(85) . 
2. Opioids 
The so-called “Weak Opioids”:
When NSAID s are not indicated as per
the mechanisms of pain, or if they provide
insufficient relief, are contraindicated, are
poorly tolerated or when pain is severe at
presentation, the addition or substitution of
a so-called “weak” opioid (mostly pro-drugs
that are metabolized by the patient into
small doses of full opioids e.g. codeine,
propoxyphene, hydrocodone, or dihy-
drocodone preparations) is recommended
as an analgesic of intermediate potency(1) .
These medications are almost exclusively
formulated as combination products; these
agents are weak only insofar as the inclu-
sion of aspirin, acetaminophen, or ibupro-
fen results in a ceiling dose above, after
which the incidence of toxicity increases.
Also in this category is included Tra-
madol , a weak agonist that combines its
weak opioid effect with potentiating activi-
ty by reuptake inhibition of noeadrenaline
and serotonin at the presynaptic level. The
advantage of this medication may lie in the
availability in different presciption presen-
tations as available in Europe (oral solution,
capsules and slow release tablets) to better
adjust dosage regimen). 
While these opioids are appropriate for
mild or intermittent pain, physician often
rely excessively on these agents, frequently
continuing their use after they are no longer
effective in an ill-advised attempt to avoid
prescribing more potent opioids that are
also more highly regulated. The potency of
hydrocodone and dihydrocodone prepara-
tions is greater than that of codeine and
propxyphene(86). These agents have per-
ceived advantage of not requiring triplicate
prescriptions (DEA Class C-III versus C-II in
the US), or special duplicated prescribing
forms (as a restricted medication in Spain),
although the clinician must be cautious not
to exceed the usual recommended dose of
paracetamol (acetaminophen 4 Gm/day) as
opioid requirements increase.
“Potent Opioids”:
When combinations of “weak” opioids
and adjuvants provide insufficient analgesia
or when pain is severe at presentation, more
potent opioids should be considered(19). Mor-
phine, hydromorphone, transdermal fen-
tanyl, and oxycodone are appropriate first-
What every professional working in palliative care should know about cancer pain management 69
line opioids for the treatment of moderate to
severe pain. Methadone, although inexpen-
sive, and to a lesser extent levorphanol are
usually reserved for special circumstances
because their half-lives are long and unpre-
dictable, introducing the potential for accu-
mulation, especially in the presence of
advanced age and altered renal function(87). 
Dosing Guidelines
Pharmacological therapy should be indi-
vidualized in light of the specific characteris-
tics and needs of each patient(88). The correct
dose of an opioid is the one that effectively
relieves pain without inducing unacceptable
side effects. Opioids should be initially be
introduced in low doses, since the early
development of side effects will impair com-
pliance, but they should be rapidly titrated to
needed effect. If side effects ensue before ade-
quate pain relief is established, they are treat-
ed aggressively in an algorithmic fashion or
other strategies should be applied(89, 90) which
are described later in this chapter.
a. Calculation of morphine equivalent
daily dose (MEDD): If the patient is
already on opioid medication, it is
recommended to calculate the
MEDD in order to administer an
equianalgesic dose of an alternate
opioid if desired. Opioid dose con-
version tables may helpful for calcu-
lation, but should be followed cau-
tiously allowing for interpatient vari-
ability in opioid side effect sensitivity.
b. Basal and Rescue dosing guidelines:
If analgesics are withheld until pain
becomes more severe, sympathetic
arousal occurs and then even potent
analgesics may be ineffective. Thus,
a time-contingent schedule for the
administration of analgesics is gen-
erally preferred to symptom-contin-
gent administration. With prolonged
administration on demand, patterns
of anticipation and memory of pain
become established and may con-
tribute to suffering, even during peri-
ods of adequate analgesia. Around-
the-clock administration of appro-
priate analgesics maintains more
even therapeutics blood levels and
decreases the likelihood of intolera-
ble pain(91). Compliance and overall
quality of analgesia are enhanced by
the regular administration of long-
acting opioid analgesics for basal
pain control, supplemented by a
short-acting opioid analgesic
administered as needed for break-
through and incident pain. In prac-
tice, controlled-release morphine,
controlled-release oxycodone or
transdermal fentanyl are available
which cannot be broken, crushed or
chewed. When these agents are
poorly tolerated, methadone or lev-
orphanol may be prescribed, but
careful monitoring is required, par-
ticularly in elderly patients.
A drug of relatively high potency,
short onset, and brief duration, such
as immediate-release morphine,
hydromorphone, oxycodone, or oral
transmucosal fentanyl citrate is
selected for as-needed administra-
tion to manage exacerbation of pain
(92). These agents should be pre-
scribed every 2-4 hours as needed.
When breakthrough medications
are used more then 2-3 times over
12 hours consistently, the dose of
basal, long-acting analgesic may be
increased. If incident pain is a signif-
icant problem, the patient should be
instructed to take the breakthrough
dose in anticipation of pain-provok-
ing activity. A new formulation of
oral transmucosal fentanyl citrate
has been shown to produce mean-
ingful relief of breakthrough pain
within 5 minutes of initiating con-
sumption, an onset that mimics
intravenous administration, despite
the noninvasive character of this
therapy (93) .
c. Agonist-antagonists and Partial Ago-
nists:Agonist-antagonist (Nalbupine,
Butorphanol) and partial agonist
(buprenorphine) opioid though effec-
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tive at the start of strong opioid therapy
are generally avoided for a variety of
reasons, the most important of which is
the presence of a clinical ceiling anal-
gesic effect, or dose above which toxi-
city but not analgesia increases. How-
ever, matrix transdermal presentation
of buprenorpine available in Europe
may make worthy the utilization
buorenorphine in patches to enable
gradual titration if intolerance to
stronger opioids is severe.
Route of administration
1. Oral: When possible, analgesics
should be administered orally or by a simi-
larly noninvasive route (transdermal, rectal,
transmucosal) to promote independence
and mobility and for ease of titration. In the
presence of a functional, intact GI system,
once the dose is adjusted to account for the
hepatic first-pass effect, oral administration
provides analgesia that is as effective as par-
enteral administration. The sublingual route
of adminstration was favored in the hospice
setting, but erratic absorption of morphine
is problematic. Buccal administration of
fentanyl in the form of oral transmucosal
fentanyl citrate has become a valuable
option for rapid analgesia in patients with
severe breakthrough pain(93).
2. Transdermal: When pain control is
inadequate with oral analgesics or the oral
route is contraindicated, alternative means
of drug delivery route should be explored.
Transdermal fentanyl provides steady plas-
ma level of analgesic for 72 hours per
applied patch. The system’s rate-controlling
membrane regulates drug release at a slow-
er rate than average skin flux, ensuring that
the delivery system rather than the skin is the
main determinant of absorption. Tempera-
ture is the most important factor in the deter-
minant of absorption, so patients should be
cautioned not to place a heating pad direct-
ly over the patch. Although low level of fen-
tanyl can be detected in the bloodstream just
an hour after administration, a consistent,
near-peak level is not obtained for 12-18
hours after treatment is initiated.
3. Rectal: Rectal route is reliable for
short-term use except in the presence of diar-
rhea, fistula, or other anatomical abnormal-
ities. Morphine and hydromorphone are
available in rectal preparations in the US,
and oxymorphone rectal suppositories pro-
vide 4-6 hours of potent analgesia(94). Rectal
methadone is also available in compound-
ed form but should be used judiciously.
4. Other routes of administration: Con-
tinuous subcutaneous or intravenous infu-
sions of opioids by means of a pump, IV or
subcutaneous PCA, and intrathecal or epidur-
al opioids administered via an externalized
catheter or internalized pump can also be
used (see interventional pain section below).
Side Effects
Constipation and miosis are the only
two opioid-mediated effects to which signi-
ficant tolerance appears never to develop.
Usually a combined mild laxative and sof-
tener (Senokot-S) is prescribed when opioid
therapy is started. Patients should be
instructed about sliding-scale regimen until
a regular bowel habit develops. An osmot-
ic agent (e.g. Lactulose) is the usual second-
line agent of choice for refractory constipa-
tion. Severe constipation may leads to fecal
impaction that requires manual disim-
paction or the sequential administration
glicerine suppositories and lavative enemas
to avoid it.
Nausea and vomiting can be so strong
that it may require rehydration. Opioid
induced nausea and vomiting usually
resolves spontaneously with continued opi-
oid use ( tolerance to side effects), and thus
patients should be reassured and encour-
aged to adhere to their prescribed regimen
of analgesics. The properistaltic agent meto-
cloprapramide is our first choice for opioids
related emesis, after ensuring constipation
is not the cause. Metoclopramide is partic-
ularly effective when gastric stasis is sug-
gested by nausea, bloating and early satiety.
Haloperidol, prochlorperazine, or chlor-
promazine are other reasonable choices,
especially when cost is in consideration(89).
Ondansetron, a 5-HT3 anatagonist is com-
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monly used as an adjunct to emetic
chemotherapies, is sometimes useful, but is
very expensive. Dronabinol and corticos-
teroids are other treatments for refractory
nausea.
Opioid induced sedation that fails to
improve with time can often be managed
effectively with a psychostimulant such as
methylphenidate or dextroamphetamine(90).
When side effects are refractory to
above mentioned medications trials, opioid
rotation should be considered, since side
effects are often idiosyncratic and may not
be triggered by agents that are in other
respects quite similar. If patients have per-
sistent refractory side effects, more invasive
modalities should be considered.
Opioid addiction is always a fear in
patients receiving opioid medication,
which is defined as a psycho-behavioral
phenomenon with possible genetic influ-
ence characterized by overwhelming drug
use, nonmedical drug use, and continued
use despite the presence or threat of physi-
ological or psychological harm. Physicians
should be able to differentiate addiction
from tolerance, which is defined as the need
for increasing dosages over time to maintain
a desired effect, and physical dependence,
a state characterized by the onset of char-
acterized withdrawal symptoms when a
drug is precipitously stopped or a specific
antagonist is administered. Tolerance and
physical dependence are biophysical phe-
nomenon that are inevitable and should be
regarded as pharmacological effects.
Patient and family education should clarify
these issues to aid in patient compliance
with the prescribed regimen. This education
is an essential element of a successful pain
relief program. 
Chronic administration of meperidine
(also known as petidine) , leads to accumu-
lation of normeperidine, a metabolite that
may lead to frank seizure activities, espe-
cially when renal function is impaired(95).
Thus, meperidine has fallen from favor as a
useful analgesic agent in the treatment of
cancer related pain.
3. Adjuvant analgesics
The aim of adjuvant therapy is to elicit an
additive or synergistic effect or to diminish the
toxicity of the primary therapy. In context of
cancer pain, either it enhances opioid-medi-
ated analgesia, diminishes opioid-mediated
side effects or improves other symptoms asso-
ciated with cancer(96). This analgesics are het-
erogeneous group of medications originally
developed for purposes other then relief of
pain that have observed to promote analge-
sia in specific clinical settings. 
It is important fact to remember that (a)
Not every agent belonging to each compo-
nent drug class appears to posses analgesic
properties, (b) even agents with confirmed
analgesic properties relieve only specific
types of pain derived from specific selected
conditions and (c) even then, pain relief does
not accrue in all affected patients. A brief
summary of these drugs is presented here:
I. Sequential drug trials: The recognition
that neuropathic pain often fails to respond
adequately to the routine administration of
opioid and often responds in a binary fash-
ion (no response or partial response) to
many adjuvants titrated over time, underlies
the contemporary concept of sequential tri-
als. Candidates are best initiated singly in
low doses and titrated upward over time (2-
4 weeks) until analgesia is achieved, side
effects supervene, or the agent under trial
can be excluded and a new trial can be
commenced(96) .
II. Antidepressants: The efficacy of
selected antidepressant as analgesics per se,
independent of their effects on mood and
nighttime sleep, has been demonstrated
mostly in non-cancer models, although util-
ity has been demonstrated for some agents
in cancer patients as well(97-104). The antide-
pressant characteristically induce analgesia
in responders with doses generally consid-
ered insufficient to relieve depression
argues for a direct, independent underlying
mechanism of effect. In addition, although
onset is not immediate, analgesia is gener-
ally established more rapidly than are anti-
depressant effects (typically 3-7 days versus
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14-21 days). The operant mechanism for
antidepressant-mediated analgesia presum-
ably relates to increased circulating pools of
norepinephrine and serotonin induced by
reductions in the postsynaptic uptake of
these neurotransmitters. It is also observed
that co-administration of at least Amitripty-
line and Clomipramine increases plasma
morphine levels(103) .
Tricyclic antidepressants are used for
patients with neuropathic pain (e.g. pos-
therpetic neuralgia, central pain, diabetic
neuropathy), headache, arthritis, chronic
low-back pain, and psychogenic pain(96).
The main indication is neuropathic pain
that is relatively constant and unrelenting
and that is not predominantly intermittent,
lancinating, jabbing, or shocklike. Paroxys-
mal neuropathic pain may also be treated
effectively with tricyclic antidepressants but
is often first treated with an anticonvulsant.
Amitriptyline and to a lesser extent
imipramine remain the most extensively
studied of these agents, and as a result they
are the usual first choices. Although rela-
tively innocuous, side effects are especially
prominent with these agents. Their metabo-
lites include nortriptyline and desipramine
which both have a better side effects profile.
Some physician may prefer to start with nor-
triptyline or desipramine as a first line ther-
apy. Since newer the newer class of antide-
pressants, the SSRIs (fluoxetine, paroxitine,
sertraline, and others) are less effective for
treating pain then above-mentioned agents,
they may have efficacy in treating depres-
sion associated with pain.
Usually amitriptyline, nortriptyline, or
desipramine is started at 10-25 mg nightly
and gradually titrated upward, usually to a
range of 50 to 125 mg and occasionally
higher, until toxicity occurs or analgesia is
established. Dry mouth, constipation,
drowsiness, and dysphoria are the most
prominent of a wide range of side effects,
which include urinary retention and cardiac
dysrhythmia. Unlike the opioids, the devel-
opment of tolerance is less robust, and side
effects are less readily reversible. So if side
effects are more prominent then analgesia,
the offending agent is usually discontinued
and a pharmacological analog or a drug
from another class is started. The newer
SSRI’s may be preferred over the hetero-
cyclic agents for fragile elderly patient, or in
patients predisposed to developing anti-
cholinergic side effects, patients whom
multiple trials of tricyclics have failed
because of side effects, and when depres-
sion is a prominent co-morbidity.
III. Anticonvulsants: Carbamazepine,
phenytoin, valproate, clonazepam, and
most recently gabapentin, alone or in com-
bination with the tricyclic antidepressants,
have been shown to successfully treat neu-
ropathic pain(104). Most authorities consider
them as first choice for neuropathic pain and
second-line therapy for relatively steady,
constant neuropathic pain when tricyclic
antidepressants are poorly tolerated, ineffec-
tive, or only partially effective(96). Anticon-
vulsants dampen ectopic foci of electrical
activity and spontaneous discharge from
injured nerves, in a manner analogous to
their salutary effects in seizure disorders.
Although carbamazepine therapy has
been most thoroughly studied anticonvul-
sant for the treatment of neuropathic pain,
it has largely been replaced by the newer
and safer anticonvulsants including
gabapentin. Gabapentin is a newer anticon-
vulsant and considered efficacious and well
tolerated for neuropathic pain(105) . It should
be started by tolerance in doses at 300 to
600 mg per day and subsequently increased
up to a maximun of 900 mg three or four
times a day until analgesia obtained or side
effects developed. Occasionally, patients
respond to much higher doses of
gabapentin without side effects. Felbamate
is also known to interact with NMDA recep-
tors, but its use is limited secondary to aplas-
tic anemia. Other well tolerated newer anti-
convulsants include topiramate, levitirac-
etam, tiagabine, oxcarbazepine, lamotrig-
ine, and zonisamide, but their use on this
indication has not been extensively studied.
IV. Baclofen: Baclofen is a g-amino
butyric acid (GABA) agonist, which
although generally used for spasticity, has
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been reported to be effective for lancinat-
ing, tic like neuropathic pain. It is usually
started at 5 mg twice or three times day or
and may be titrated up to 30-90 mg/day, as
tolerated. It is also useful for spasticity; espe-
cially due to spinal cord injury and multiple
sclerosis in the intrathecal route(106).
V. Oral local anesthetics: Oral mexile-
tine is drug from the class III anthiarrytmics
used initially as a disproved diagnostic
intervention in neuropathic pain, and later
as an adyuvant, usually regarded as a third-
line association agent for continuous or
intermittent neuropathic pain disorders.
Acting as a non-selective Na+ channel
blocker , several studies have shown disap-
pointing efficacy and an important rate of
side effects when use in dosis greater than
300 mg a day. No other oral local anesthet-
ic is currently recommended 
VI. Amphetamines: The most widely
accepted use for amphetamines in the treat-
ment of cancer pain is as a means to reverse
opioids induced sedation(107). Research sug-
gests that dextroamphetamine and
methylphenidate possess some analgesic
properties and are excellent antidepres-
sants(108). The amphetamines are well toler-
ated by cancer patients and instead of induc-
ing anorexia, these agents typically have a
paradoxical effect of increasing appetite by
enhancing alertness. Nervousness and agi-
tation are the most common side effects. 
VII. Corticosteroids: Corticosteroids are
known for its efficacy for treatment of acute
pain resulting from raised intracranial pres-
sure and spinal cord compression second-
ary to its effect in reducing peritumoral ede-
ma and inflammation with consequent
relief of pressure and traction on nerves and
other pain-sensitive structures. Improve-
ments in symptoms are often rapid and dra-
matic but usually depend on continued
administration. This effects are short-lived
and usually level off in few weeks. 
Dexamethasone is the usual drug of
choice because it has less potent mineralo-
corticoid effects. Side effects ranged from
dysphoria and diabetes mellitus to florid
psychosis. For oncologic emergencies, 100
mg of dexamethasone should be adminis-
tered as bolus dose, followed by intra-
venous maintenance dose. The large bolus
dose produces severe but transient perineal
burning via unknown mechanism. For non-
emergencies, dose is 2-6 mg three or four
times a day.
VIII. N-Methyl-D-Aspartate Antago-
nists: The NMDA receptor has been well
described and implicated in the transmis-
sion of pain. Ketamine and dextromethor-
phan, partial NMDA antagonists, appear to
mediate pain by this mechanism. Subanes-
thetic doses of ketamine have been admin-
istered for prolonged periods with fair suc-
cess in a small number of patients with
refractory neuropathic cancer pain(109,110).
Because of side effects, ketamine infusion
should be reserved as a late treatment for
highly refractory neuropathic pain.
IX. Alpha-2 Adrenergic antagonists:
The centrally acting antihypertensive cloni-
dine has been observed to promote analge-
sia for neuropathic pain when administered
near the neuraxis. Epidural administration
has received U.S. Food and Drug Adminis-
tration (FDA) approval. In a prospective
randomized study of 38 patients with
severe cancer pain(111) that persisted despite
large doses of spinal opioids, the addition
of epidural clonidine was associated with
significant improvement in 45% of patients
overall and 56% of patients with neuro-
pathic pain. Hypotension during the initia-
tion and rebound hypertension during
withdrawal are the main potential risk of
treatment.
X. Other adyuvants: Strontium is an
analogue of calcium and is taken up by the
skeleton into active sites of bone remodel-
ing and metastasis. A large clinical trial
demonstrated that a 10 micro curie IV dose
was an effective adjuvant to local radiother-
apy, and that it reduced disease progression,
decreased new sites of pain, and decreased
systemic analgesics use(112 ). It is also a use-
ful adjuvant for diffuse metastatic bone
pain. The latency of response can be as long
as 2-3 weeks, in which case patients must
be instructed to continue analgesic therapy. 
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The biphosphonate pamidronate disodi-
um, inhibits osteoclastic bone resorption
and has been shown to reduce pain and
skeletal complications, such as pathological
fracture in breast cancer patients and multi-
ple myeloma(113,114 ). The drug is adminis-
tered in a 90 mg intravenous infusion in 2 hr
approximately every 4 weeks. Excellent
reviews of the literature on this topic are eas-
ily available and recommended to read(115).
Interventional Pain Management
When a comprehensive trial of pharma-
cological therapy fails to provide adequate
analgesia or leads to unacceptable side
effects, consideration should be given to
alternative modalities.
1. Continuous subcutaneous infusion
of opioids (CSCI): It is an excellent option
for patients whose medical condition pre-
cludes the use of the oral route or whose
pain is poorly controlled despite large dos-
es of oral opioids(116, 117).
Starting doses are calculated based on
the 24-hour dose requirement of intra-
venous morphine with a conversion table
and divide it by 24, which gives the hourly
rate. Tissue irritation is minimized when vo-
lumes under 1 to 2 ml/hour are prescribed
(by concentrating the mixture). A 27-gauge
butterfly needle is inserted subcutaneously
anywhere with the most preferred sites
including the infraclavicular fossa or chest
wall for the ease of ambulation.
Absorption of subcutaneously adminis-
tered opioids is rapid, and steady-state plas-
ma levels are generally approached within
an hour(117). Most parenteral opioids are suit-
able for CSCI, although morphine and
hydromorphone are used most commonly
and meperidine, methadone and penta-
zocine should be avoided because of the
potential for tissue irritation. Rescue doses
should be given as subcutaneous injection
equal to the hourly dose to be administered
every 1-2 hour as need. 
2. Continuous intravenous infusion of
opioids (CII): This modality is indicated in a
group of patients include intolerance of the
oral route because of GI obstruction, mal-
absorption, opioid induced vomiting, dys-
phagia, or the requirement of large number
of pills. It is also indicated in a patient get-
ting prominent bolus effect with intermittent
injection, the necessity for rapid titration
and requirement of bolus injections that
exceed nursing capabilities. It is very simi-
lar to CSCI, although CSCI is preferred in the
home care setting unless a permanent vas-
cular access device is already in place(117) . 
Patient controlled analgesia (PCA) is a
similar version and excellent option but is
reserved for patients with the capacity to
understand and use this modification cor-
rectly. Dose should be adjusted upward
until pain relief is adequate or side effects
become intolerable.
3. Intraspinal Analgesia: Neuraxial
analgesia is achieved by the epidural or
intrathecal administration of an opioids
alone or in combination with other agents.
With the use of neuraxial analgesia, pain
relief is obtained in a highly selective fash-
ion with an absence of motor, sensory, and
sympathetic effects, making these modali-
ties highly adaptable to the home care envi-
ronment(118-122). The principle of neuraxial
opioid therapy is that introducing minute
quantities of opioids in close proximity to
their receptors (substantia gelatinosa of the
spinal cord) achieves high local concentra-
tions(119). With this therapy, analgesia may
be superior to that achieved when opioids
are administered by other routes, and since
the absolute amount of drug administered is
reduced, side effects are minimized. 
The neuraxis can be accessed via an
intrathecal, epidural, or intraventricular
approach, although the intraventricular
route is used infrequently, primarily for
intractable head and neck pain, and then
usually when an access device (Ommaya
reservoir) is already in place(123). The most
important aspect of this therapy is its
reversibility and the reliability and simplic-
ity of advance screening measures to con-
firm efficacy. Screening can generally be
accomplished on an outpatient basis by
What every professional working in palliative care should know about cancer pain management 75
observing the patient’s response either to a
morphine infusion via a temporary percuta-
neous epidural catheter or a single-shot
intrathecal injection. If improved pain con-
trol and reduced side effects are sufficient-
ly profound to warrant more prolonged
therapy either with temporary catheter for
period of days to weeks or replacement with
a permanent implanted catheter along with
implanted medication deliverable pump. 
Chronic administration of epidural opioids
can be accomplished by intermittent bolus
administered by the patient, family mem-
bers, nursing personnel, or more common-
ly by continuous infusion via a standard
PCA portable infusion pump connected to
the epidural port. Continuous infusion is a
preferred means of administration because
intervals of pain between injections are
avoided. More commonly a combination of
epidural opioids and dilute local anesthet-
ics agents have been determined to be safe
and are often beneficial for pain that is
refractory to opioids alone(124).
Subarachnoid catheter placement is an
alternative to epidural administration. Opi-
oids requirements are less than with epidur-
al administration because of more direct
access to the spinal cord. Many factors are
considered in the decision for an external
pump system versus an implantable pump.
These include factors that lead us to an
external system: a short life expectancy (< 3
months), the need for frequent patient con-
trolled doses (such as with severe incident
pain), the need for an epidural infusion
(which generally requires infusion volumes
too great for the implanted pump), the lack
of reprogramming/refilling capabilities near
the patient’s home, or payor constraints. We
use a variety of catheters for our external
systems including a tunneled Arrow Flex-
Tip catheter, the Du Pen’s epidural catheter,
and the Sims epidural portacath.
Factors that lead us to consider an
implantable intrathecal pump include: a
longer life expectancy (> 3 months), access
to pump refill/reprogramming capabilities,
diffuse pain (e.g.- widespread metastasis),
and favorable response to an intrathecal tri-
al. We use a programmable (Synchromed,
Medtronic, Inc., Minneapolis MN) pump for
permanent implantation.
A recently published multicenter
prospective randomized clinical trial by
Smith, et al., compared intrathecal therapy
to continued medical management reveal-
ing a slight trend toward better analgesia in
the intrathecal group (not statistically signif-
icant), but improved side effect profile and
increased survival in the intrathecal
group(125). Our group reported a significant
improvement in pain scores (NRS 7.9 to 4.1)
and decrease from 588 mg/day oral mor-
phine equivalents to 294 mg/day following
intrathecal analgesia(126).
Neuraxial medication is expensive, par-
ticularly as to whether an implanted pump
is a justifiable expense in a patient with a
limited life expectancy. Two studies evalu-
ated the external versus internal pump, with
the ongoing costs of external pump lease
and tubing versus the high initial cost of the
implanted pump. These analysis show a
“break even” point at approximately 3
months(127, 128).
Recently Hassenbusch and colleagues
published current practice data on intrathecal
medication management. A survey of 413
physicians managing 13,342 pts was per-
formed. It showed a variety of medications
being used in the intrathecal pump including:
morphine (48%), morphine/bupivacaine
(12%), hydromorphone (8%), morphine/cloni-
dine (8%), hydromorphone/clonidine (8%),
morphine/clonidine/bupivacaine (5%), mor-
phine/baclofen (3%), and others (< 3%). Oth-
er drugs mentioned included: fentanyl, sufen-
tanil, ziconotide, meperidine, methadone,
ropivacaine, tetracaine, ketamine, midazo-
lam, neostigmine, droperidol, and nalox-
one(129).
Side effects in forms of nausea, respira-
tory depression, pruritus, urinary retention,
dysphoria are common for opioid-naïve
patients, but are extremely rare in opioid-
tolerant individuals(118).
4. Neural Blockade Techniques: 
a. Local anesthetic nerve blocks: Local
anesthetic injections can be broadly
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classified as being applicable for
diagnostic, and/or therapeutic pur-
poses(130-139).
a1. Diagnostic Blocks: Diagnostic
blocks help to characterize the
underlying mechanism of pain
(nociceptive, neuropathic, sym-
pathetically mediated) and to
discern the anatomical path-
ways involved in pain transmis-
sion. Its main indication is as a
preliminary intervention con-
ducted prior to a therapeutic
nerve block or other definitive
therapy. This helps the clinician
to determine the potential for
subsequent neurolysis if indi-
cated. While results often have
good predictive value, they are
not entirely reliable.
a2. Therapeutic blocks: The role of
this block in cancer patients is
limited typically because of
transient nature of attendant
pain relief. Therapeutic injec-
tions of local anesthetics, with
or without corticosteroid, into
trigger points, subcutaneous
foci of localized muscle spasm,
may provide lasting relief of
myofascial pain(134). This bed-
side procedure is particularly
useful when muscle spasm arise
as a result of prolonged bed rest
and for pain that follows thora-
cotomy, mastectomy, or radical
neck dissection. Diffuse subcu-
taneous injection of coricos-
teroids and local anesthetics
may be useful in acute herpes
zoster or post-herpetic neural-
gia. Epidural steroid-local anes-
thetics injection are unlikely to
provide lasting relief for back
pain due to progressive neo-
plastic lesions. Local anesthetic
injections administered in a
series may contribute to lasting
pain relief in the setting of post-
traumatic sympathetically
maintained pain (e.g. reflex
sympathetic dystrophy or com-
plex regional pain syn-
drome)(135-137). Although infre-
quent, such symptoms may
arise as a result of tumor inva-
sion of nervous system structure
(e.g. brachial or lumbosacral
plexopathy), in which case
either local anesthetic blockade
of the stellate ganglion or lum-
bar sympathetic chain has been
used with some success to
relieve pain. 
b. Neurolytic nerve blocks: Neurolytic
blocks have played an important role
in the management of intractable
cancer pain. This modality should be
offered when pain persists despite
thorough trials of aggressive pharma-
cological management or when drug
therapy produces unwanted and
uncontrollable side effects. Patient
selection is important, including: (a)
severe pain, (b) pain is expected to
persist, (c) pain cannot be modified
by less invasive means, (d) pain is
well-localized, (e) pain is well-char-
acterized, (f) pain is not multi-focal,
(g) Pain is of somatic or visceral ori-
gin, (h) patient with limited life
expectancy.
Alcohol and Phenol are the only agents
commonly used to produce chemical neu-
rolysis. Ethyl alcohol is a pungent, colorless
solution that can be readily injected through
small-bore needles and that is hypobaric
with respect to CSF. For peripheral and sub-
arachnoid blocks, alcohol is generally used
undiluted (referred to as 100% alcohol,
dehydrated alcohol, or absolute alcohol),
while a 50% solution is used for celiac
plexus block. It should not be exposed to
atmosphere, because absorbed moisture
dilutes it. Alcohol injection is typically fol-
lowed by intense burning pain and occa-
sionally erythema along the targeted nerve
distribution. Denervation and pain relief
sometimes accrue over a few days follow-
ing injection. 
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Phenol is fairly unstable at room tem-
perature. It lasts at least one year when
refrigerated and kept away from light. Phe-
nol can be used in 3-15 % concentration
and with saline, water, and glycerol or radi-
ological dye. It is relatively insoluble in
water, and as a result concentration in
excess of 6.7 % cannot be obtained at room
temperature without adding glycerine to
increase its solubility in water. Phenol with
glycerine is hyperbaric (versus alcohol
being hypobaric) in CSF, but is so viscid that
even when warmed, it is difficult to inject
through needles smaller then 20 gauge.
Phenol has a biphasic action-its initial local
anesthetic action produces subjective
warmth and numbness that usually give
way to chronic denervation over a day’s
time. Hypoalgesia after phenol typically is
not as dense as after alcohol, and quality
and extent of analgesia may fade slightly
within the first 24 hours of administration.
Subarachnoid (intrathecal) injections of
alcohol or phenol continue to play an
important role in the management of
intractable cancer pain in carefully selected
patients. Neurolytic neuraxial block pro-
duces pain relief by chemical rhizotomy.
Since alcohol and phenol destroy nervous
tissue indiscriminately careful attention to
the selection of the injection site, volume
and concentration of injectate, and selec-
tion and positioning of the patient are essen-
tial to avoid neurological complications(139-
141). Most authorities agree that neither alco-
hol nor phenol offers a clear advantage
except insofar as variations in baric proper-
ties facilitate positioning of the
patient(142,143). Except for perineal pain, alco-
hol is usually preferred, since most patients
are unable to lie on their painful side, as is
required for intrathecal phenol neurolysis.
In one of the analysis of 13 published series
documenting treatment with intrathecal rhi-
zolysis of more than 2500 patients Swerd-
low reported that 58% of patients obtained
“good” relief; “fair” relief was observed in
an additional 21%, and in 20% of patients
“little or no relief” was noted(142). Average
duration of relief is estimated at 3 to 6
months, with a wide range of distribution.
Reports of analgesia persisting 1 to 2 years
are fairly common(144). In representative
series using alcohol (n= 252) and phenol (n
= 151), a total of 407 and 313 blocks were
performed respectively (145,146). In these two
series, neither motor weakness nor fecal
incontinence occurred, and of 8 patients
with transient urinary dysfunction, inconti-
nence persisted in just 1. 
Subarachnoid neurolysis can be per-
formed at any level up to the mid-cervical
region, above which the risk of drug spread
to medullary centers and the potential for
cardiorespiratory collapse increases(147).
Blocks in the region of the brachial outflow
are best reserved for patients with preexist-
ing compromise of upper limb function.
Similarly, lumbar injections are avoided in
ambulatory patients, as are sacral injections
in patients with normal bowel and bladder
function. Hyperbaric phenol saddle block is
relatively simple and is particularly suitable
for many patients with colostomy and uri-
nary diversion. Until recently, epidural neu-
rolysis was performed infrequently. Results
were inferior to those obtained with sub-
arachnoid blockade, presumably because
the dura acts as a barrier to diffusion, result-
ing in limited contact between the drug and
targeted nerves(144, 148).
Sympathetic blockade also produces
prolonged relief of pain in cases where the
pain is sympathetically mediated(135,136) .
When local anesthetic sympathetic blocks
provide only temporary relief or when clin-
ical findings suggest visceral or sympathet-
ically mediated pain, consideration of
chemical sympathectomy is warranted.
Celiac plexus block continues to be one
of the most efficacious and common nerve
blocks employed in patients with cancer
pain(130). It has great potential for relieving
upper abdominal and referred back pain
secondary to malignant neoplasm involving
structures derived from the foregut (distal
esophagus to mid-transverse colon, liver,
biliary tree, and adrenal glands). The most
common indication for celiac axis block is
pancreatic cancer. Celiac axis block is most
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commonly performed by positioning nee-
dles bilaterally either antero- or retrocrural-
ly via a posterior percutaneous approach 
The retrocrural technique is more accu-
rately called a splachnic nerve block.
Despite the proximity of major organs (aorta,
vena cava, kidneys, pleura) and the require-
ments for a large volume of neurolytic (30-
50 ml of 50% alcohol in the anterocrural
technique, much less volume in the retro-
crural) complication rates are uniformly low,
although some complications are serious(149-
151). In contemporary practice most authori-
ties consider radiological guidance manda-
tory to verify needle placement(151). Tradition-
ally fluoroscopy has been used, but CT guid-
ance is increasing in popularity because
vascular structures, viscera, and masses can
be visualized(152). Although studies have been
criticized for methodological deficiencies,
85 to 94% incidence of good to excellent
relief of pain has been obtained in large series
of patients undergoing one or more neurolyt-
ic celiac plexus blocks for pain from pancre-
atic cancer, or a variety of intraabdominal
neoplasms(153). In one of the randomized
double-blind, placebo-controlled study of
intraoperative celiac neurolysis demonstrat-
ed that treated patients had not only
improved pain control, reduction in opioid
use and improved function but also statisti-
cally significant improvement in survival(7) .
This issue has very recently been submitted
again through a well designed methanalysis
by the Mayo Clinic group, and has reaffirmed
the efficacy in decreasing pain rating within
the several weeks after the block, and
decreasing the opioid requirements then on
. Unfortunately they have not found signifi-
cant effects in the quality of life indexes when
compared to standard pharmachological
treatment(50). Our group at MD Anderson
Cancer Center has reported in abstract form
a retrospective study revealing an 83%
reduction in pain score and 73% reduction
in MEDD after splachnic nerve block(154).
Stellate ganglion block, with repeated
local anesthetic of the sympathetic outflow
to the head, neck, and arm often provide
persistent relief of sympathetically main-
tained pain affecting these regions. Stellate
ganglion neurolysis is hazardous because of
the close proximity of other important struc-
tures (brachial plexus, laryngeal nerves,
epidural and subarachnoid space, vertebral
artery) and the potential for injury because
of inaccurate needle placement. If local
anesthetic injections have been document-
ed to provide temporary relief of pain, sur-
gical extirpation of the ganglia may be con-
sidered, or neurolysis may be performed
cautiously using radiological guidance and
small volumes of injectate(155).
Neurolytic lumbar sympathetic block is
most applicable for pain in the lower
extremities due to lymphedema or reflex
sympathetic imbalance, although it has also
been applied for rectal and pelvic pain in
anecdotal fashion(131). 
Superior hypogastric plexus block(156) is
generally preferred for intractable chronic
pelvic or rectal pain of neoplastic origin. In
contrast to subarachnoid injection, risks of
bowel, bladder, and motor dysfunction with
either lumbar sympathetic or hypogastric
block, even when performed bilaterally, are
extremely low, particularly with radiologi-
cal guidance. 
In the first published study of superior
hypogastric block(156), 28 patients with
intrapelvic neoplasms or radiation enteritis
were studied, and all had significant or
complete relief of pain with no complica-
tions. In all but 2 patients with pain due to
neoplasm, relief persisted until death (3 to
12 months). In another study of 26 cancer
patients with severe (10 out of 10 intensity)
intractable pelvic pain: 70% had satisfacto-
ry relief (less than 4 out of 10 intensity) and
the remaining patients, moderate relief (4
to7 of 10)(157). Complications were not
observed, and no patients with satisfactory
relief required repetition out to a 6 month
follow up.
The ganglion impar is a solitary
retroperitoneal structure at the level of the
sacrococcygeal junction that marks the ter-
mination of the paired paravertebral sympa-
thetic chains. Although the anatomical inter-
connections of the ganglion impar are rarely
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described in any detail, even in the anatomy
literature, the sympathetic component of
perineal pain syndromes appears to derive
at least in part from this structure. The first
report of interruption of the ganglion impar
for the relief of anal, genital, or perineal can-
cer related pain appeared in 1990(158). Of 16
patients, 8 had complete, durable relief of
pain, and the remainder had significant
reductions in pain. Blocks were repeated in
two patients with further improvement. No
complications occurred, and follow-up,
which depended on survival, was carried
out for 14 to 120 days. The technique entails
the use of a 20- or 22-gauge spinal needle
that is manually bent near its hub at about
30?. The needle is introduced through the
anococcygeal ligament with its concavity
oriented toward the concavity of the sacrum
and coccyx. Under fluoroscopic guidance
the needle is advanced until its tip lies near
the anterior surface of the junction of the
sacrum and coccyx, posterior to the rectum
where injection takes place. 
More recently, Radiofrequency-generat-
ed thermal lesions are another effective means
of inducing therapeutic nerve injury and when
directed to the tumor itself, it can have a tumo-
ricidal effect often with salutary effects on
symptoms(159) . An optimal result requires the
judicious use of fluoroscopy for placement of
needle and application of simple but essential
adjuncts including the use of a nerve stimula-
tor to avoid the motor root if applicable.
Peripheral/Cranial Nerve Blocks:
Peripheral nerve blockade has a limited role
in the management of cancer pain(139). Neo-
plastic head and neck pain is many times
difficult to control because of rich sensory
innervations of the structures. In selected
patients, blockade of involved cranial
and/or upper cervical nerves is very helpful.
Blockade of trigeminal nerve within the
foramen ovale at the base of skull or its
branches may be beneficial for facial
pain(160). If neural blockade is not effective,
intraspinal opioid therapy by means of an
implanted cervical epidural catheter or
intraventricular opioid therapy may be con-
sidered(161,162).
5. Vertebroplasty
Many cancer patients with metastatic
vertebral or osteoporotic compression frac-
tures(VCFs) present with movement-related
back pain. Percutaneous vertebroplasty
(PV) is a minimally invasive procedure
involving injecting an opacified bone
cement (usually polymethymethacrylate or
PMMA) into the fractured vertebral body to
alleviate the pain and perhaps enhance
structural. This procedure is performed by
placing needles under fluoroscopic guid-
ance with a uni- or bipedicular approach.
PMMA is injected in a carefully controlled
manner to avoid unintended cement spread
into the spinal canal. Injection is stopped as
soon as cement start approaching in poste-
rior on third of vertebral body. PV has been
shown efficacious in treating VCF related
pain in cancer patients(163). 
6. Neuromodulation:
Spinal cord stimulation is widely popu-
larized for refractory neuropathic chronic
pain states. It has limited applicability in
cancer pain states, except in ongoing chron-
ic neuropathic pain states. Selection of this
patient population is very important in can-
cer group, as MRI is contraindicated after
this devise is placed.
Neurosurgical palliative techniques
have fallen into less favor as more medica-
tions and reversible, titratable, lower risk
techniques have largely replaced these pro-
cedures. Pituitary ablation entails destruc-
tion of the gland by means of the injection
of a small quantity of alcohol through a nee-
dle positioned transnasally under light gen-
eral anesthesia. This technique is effective
in relieving pain originating from dissemi-
nated bony metastases, particularly second-
ary to hormone-dependent tumors (breast
and prostate)(164). Commissural myelotomy
has been reported to be efficacious in can-
cer pain refractory to more conservative
therapy(165). Percutaneous cordotomy pro-
duces a thermal lesion within the substance
of the spinal cord and reliably relieves uni-
lateral truncal and lower limb pain (166). As
with pituitary ablation, it necessitates a high
degree of skill and expertise, but pain relief
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is often profound and the rigors of a major
neurosurgical procedure are avoided.
Behavioral Pain Management
Different behavioral pain management
techniques have been used in patients with
cancer includes hypnosis, relaxation,
biofeedback, sensory alteration, guided
imagery, and cognitive strategies (167) . Relax-
ation and imagery training significantly
reduce visual analog scale scores in patients
who have Mucositis during bone marrow
transplant(168). This training is probably most
effective for patients who have no significant
psychological or psychiatric problems(169) and
in insightful psychology-minded patients.
Home-based and hospice care
For years together, hospice was often
incorrectly regarded as a place people go to
die, but correctly it is a philosophy of care
that is “a blend of clinical pharmacology
and applied compassionate psycholo-
gy”(170,171). In the United States hospice care
has developed primarily as a home based
service, with a minority of institutions offer-
ing short inpatient stays to stabilize refrac-
tory symptoms and to provide respite for
overwhelmed families. In Spain, a very well
organized Spanish Palliative Care Society
(SECPAL) has promoted intensively the cre-
ation of palliative care units (hospital, self
standing and ambulatory-hospital based
units) up to nearly 310 groups distributed
across most of the country’s geography with
great success. 
The principles of home-based pain man-
agement are in most respects similar to those
that apply to ambulatory and inpatient pain
management. Differences generally relate to
a recognition that further curative therapy is
futile rather than that care is being provided
at home. No compromise in quality of care
based on where it is delivered is justified. 
Hospice care is comfort oriented, focus-
ing specifically on alleviating symptoms
rather than necessarily treating their underly-
ing cause or causes. Factors that influence
the selection of home treatment are
advanced, incurable disease, realization and
acceptance of the appropriateness of pallia-
tive care (care directed at preserving comfort
and the quality of life rather than at curing the
tumor and extending life), and a desire to die
in familiar surroundings. Many difficulties
associated with providing intensive palliative
care at home can be reconciled by education
and orientation of the family and that can be
performed with coordination with health
care institutions, home care nursing, labora-
tory, and pharmacy services. 
CONCLUSIONS
Palliative Care and Pain management
are closely bounded to everyday practice.
A basic knowledge update about the current
status of concepts and techniques for Can-
cer pain management is of prime impor-
tance for every pactioner caring for Cancer
patients as a resource for appropiate infor-
mation and solution to pain problems of his
patients. As presented, Acute and chronic
pain occurs in a high frequency of cancer
patients. Inadequate assessment and treat-
ment of pain and other distressing symp-
toms may interfere with primary antitumor
therapy and markedly detract from their
quality of life . While a strong focus on pain
control is important independent of disease
stage, it is a special priority in patients with
advanced disease who are no longer candi-
dates for potentially curative therapy.
While rarely eliminated altogether, pain
can be controlled in the vast majority of
patients, usually with the careful applica-
tion of straightforward pharmacological
measures combined with diagnostic acu-
men and conscientious follow up. In the
small but significant proportion of patients
whose pain is not readily controlled with
noninvasive analgesics, a variety of alterna-
tive measures, when selected carefully, are
also associated with a high degree of suc-
cess provided by specialized in pain clinics.
An increasingly large number of anesthesi-
ologists, oncologists, and psychologists and
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other medical and non-medical professions
have come to recognize that far from an
exercise in futility, caring for patients with
advanced irreversible illness can be a high-
ly satisfying endeavor that is usually met
with considerable success. Thus, no patient
should ever wish for death or think in
euthanasia as a result of inadequate control
of pain or other symptoms, and clinicians
must never communicate overtly or indi-
rectly that nothing more can be done. Com-
prehensive cancer care is best regarded as
a continuum that commences with preven-
tion and early detection, focuses intensely
on curative therapy, and ideally is rendered
complete by a seamless transition to pallia-
tion and attention of quality of life.
The future of cancer pain relief is bright,
as much mechanistic research is looking into
different groups of specifically targeted med-
ications including tumor necrosis alpha recep-
tor antagonists, inhibitors of glutamate release,
substance P inhibitors, nitric oxide synthetase
inhibitors, and other novel compounds.
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